<DOC>
	<DOCNO>NCT01616238</DOCNO>
	<brief_summary>The NCRI Adult ALL sub-group propose collaborate Dutch/Belgian group HOVON carry prospective , non randomise multi-arm study ( include choice regimen intensity ) investigate safety , tolerability feasibility standardise therapy protocol patient ≥ 60 year old de novo ALL . The overall aim define basic standard care upon trial novel therapy base future . The design study enable collection comprehensive dataset regard clinical outcome , Complete Response Rate ( CR ) Minimal Residual Disease ( MRD ) response rate previously completely uncharacterised population , thus provide essential platform design future randomise advanced phase study new therapeutic approach novel therapy prospectively investigate .</brief_summary>
	<brief_title>A Study Older Adults With Acute Lymphoblastic Leukaemia</brief_title>
	<detailed_description>The study 1. establish baseline expectation Event Free Survival ( EFS ) , Overall Survival ( OS ) , MRD responses quality life measure old patient age pre-morbid state ; 2. disclose best use knowledge pre-morbid characteristic apply appropriate intensity therapy order balance best disease relate outcome quality life ; 3. establish national standard care patient group ; 4. provide essential platform careful design future randomise advanced phase study new therapeutic approach agent .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Age ≥ 60 Acute Lymphoblastic Leukaemia ( ALL ) OR ≥ 55 Acute Lymphoblastic Leukaemia ( ALL ) unsuitable UKALL14 HOVON 100 trial Newly diagnose , previously untreated ALL ( steroid prephase 57 day may give trial registration ) ) Willing able give consent Known HIV infection Blast transformation CML Mature Bcell leukaemia i.e . Burkitts disease ( 8,14 ) ( q24 ; q32 ) variant cmyc translocation e.g . ( 2 ; 8 ) ( p12 ; q24 ) , ( 8 ; 22 ) ( q24 ; q11 ) Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>